Production of 143 overpriced medicines of 31 manufacturers suspended by DRAP Crackdown on unauthorized increase in price of medicines resulted in seizure / not to dispose of stocks of 143 medicines. Production activities of pharmaceutical units for their overpriced medicines stopped for further action as per law. Federal Minister and Secretary National Health Services, Regulations and Coordination direct DRAP to take strict action against pharmaceutical companies selling medicines on exorbitant prices. Recommendation of registering cases on overpriced medicines under Drug Act, 1976 and DRAP Act 2012 and imposing heavy fines with recovery of overpriced amount. Spokesman of DRAP has issued a statement that strict action has been initiated against unauthorized increase in price of medicine by pharmaceutical companies. The action has been taken on receiving various complaints that pharmaceutical companies have increased prices of their drugs over and above maximum retail price (MRPs) by the federal government. Federal Minister of NHSR&C, Mr. Aamer Mehmood Kiyani directed DRAP to conduct market surveys for determination of overpricing. During a country wise activity, DRAP has taken action against 31 pharmaceutical companies and seized/ not to dispose of their 143 medicines on overpricing. Cases will be registered against these companies under SRO 913(I)/ 2017 on overpricing for recovery of overpriced amount. DRAP has advised to monitor MRPs in the market to ensure that MRPs of drugs were not higher than the notified prices. In case of stocks available in the retail shops or manufactured or imported prior to issuance of SROs must be sold at previous MRPs printed on the label in the manner prescribed by the Drugs (Labelling and Packing) Rules, 1986 while stickers or cuttings are not allowed. Moreover, DRAP has also initiated suspension of production activities of pharmaceutical companies for those products caught overpriced in the market than the notified price.
PREVIOUS NEXT
